<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wennerberg E</submitter><funding>NCI NIH HHS</funding><pagination>eabe8195</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9256502</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(636)</volume><pubmed_abstract>Most patients with non-small cell lung cancer (NSCLC) do not achieve durable clinical responses from immune checkpoint inhibitors, suggesting the existence of additional resistance mechanisms. Nicotinamide adenine dinucleotide (NAD)-induced cell death (NICD) of P2X7 receptor (P2X7R)-expressing T cells regulates immune homeostasis in inflamed tissues. This process is mediated by mono-adenosine 5'-diphosphate (ADP)-ribosyltransferases (ARTs). We found an association between membranous expression of ART1 on tumor cells and reduced CD8 T cell infiltration. Specifically, we observed a reduction in the P2X7R&lt;sup>+&lt;/sup> CD8 T cell subset in human lung adenocarcinomas. In vitro, P2X7R&lt;sup>+&lt;/sup> CD8 T cells were susceptible to ART1-mediated ADP-ribosylation and NICD, which was exacerbated upon b</pubmed_abstract><journal>Science translational medicine</journal><pubmed_title>Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer.</pubmed_title><pmcid>PMC9256502</pmcid><funding_grant_id>R01 CA198533</funding_grant_id><funding_grant_id>P30 CA008748</funding_grant_id><pubmed_authors>Lorenz IC</pubmed_authors><pubmed_authors>Adusumilli PS</pubmed_authors><pubmed_authors>Hung C</pubmed_authors><pubmed_authors>Wennerberg E</pubmed_authors><pubmed_authors>Kamel MK</pubmed_authors><pubmed_authors>Rudqvist NP</pubmed_authors><pubmed_authors>Van Nest SJ</pubmed_authors><pubmed_authors>Markowitz GJ</pubmed_authors><pubmed_authors>McGraw TE</pubmed_authors><pubmed_authors>Demaria S</pubmed_authors><pubmed_authors>Valeta-Magara A</pubmed_authors><pubmed_authors>White TE</pubmed_authors><pubmed_authors>Zhou XK</pubmed_authors><pubmed_authors>Khan AG</pubmed_authors><pubmed_authors>Balderes PJ</pubmed_authors><pubmed_authors>Borczuk AC</pubmed_authors><pubmed_authors>Chen C</pubmed_authors><pubmed_authors>Altorki N</pubmed_authors><pubmed_authors>Stiles BM</pubmed_authors><pubmed_authors>Mittal V</pubmed_authors><pubmed_authors>Agrusa CJ</pubmed_authors><pubmed_authors>Mukherjee S</pubmed_authors><pubmed_authors>Narula N</pubmed_authors><pubmed_authors>Nasar A</pubmed_authors><pubmed_authors>Spada S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer.</name><description>Most patients with non-small cell lung cancer (NSCLC) do not achieve durable clinical responses from immune checkpoint inhibitors, suggesting the existence of additional resistance mechanisms. Nicotinamide adenine dinucleotide (NAD)-induced cell death (NICD) of P2X7 receptor (P2X7R)-expressing T cells regulates immune homeostasis in inflamed tissues. This process is mediated by mono-adenosine 5'-diphosphate (ADP)-ribosyltransferases (ARTs). We found an association between membranous expression of ART1 on tumor cells and reduced CD8 T cell infiltration. Specifically, we observed a reduction in the P2X7R&lt;sup>+&lt;/sup> CD8 T cell subset in human lung adenocarcinomas. In vitro, P2X7R&lt;sup>+&lt;/sup> CD8 T cells were susceptible to ART1-mediated ADP-ribosylation and NICD, which was exacerbated upon b</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2025-05-29T19:36:41.589Z</modification><creation>2024-11-06T07:25:03.791Z</creation></dates><accession>S-EPMC9256502</accession><cross_references><pubmed>35294260</pubmed><doi>10.1126/scitranslmed.abe8195</doi></cross_references></HashMap>